RSS Feeds
The ADVANTAGE Seeding Trial: A Review of Internal Documents
- Kevin P. Hill, MD, MHS;
- Joseph S. Ross, MD, MHS;
- David S. Egilman, MD, MPH; and
- Harlan M. Krumholz, MD, SM
- From McLean Hospital, Belmont, Massachusetts; Mount Sinai School of Medicine, New York, New York; Brown University, Providence, Rhode Island; and Yale University School of Medicine and Yale-New Haven Hospital, New Haven, Connecticut.
-
Figure 1. Merck commends marketing division's ADVANTAGE Trial.Merck executives nominate those responsible for the design and execution of ADVANTAGE for an internal marketing award. A& = arthritis and analgesia; CDP = clinical development program; NSAID = nonsteroidal anti-inflammatory drug; OA = osteoarthritis. USHS = United States Human Health.
-
Figure 2. Merck slide defining the role of the marketing division in the ADVANTAGE Trial.CDP = Clinical Development Program; CRO = Clinical Research Organization.
-
Figure 3. Merck document tracking the average number of new prescriptions written by rheumatologists who were ADVANTAGE study group investigators.Merck tracked new prescriptions written for both Vioxx and Celebrex (celecoxib; Pfizer, New York, New York) by ADVANTAGE investigators in the months after the trial. Investigators were given a portfolio profile grade of A+ to D on the basis of their prescription history of using Merck products. Arth CR = Arthritis Clinical Report no. 9907; AVG = average; Meded = medical education branch of the Institute for Internal Research; NRX = new prescriptions; RHU = rheumatologists.
Related Clinical Content
